Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BLAZE-1: Bamlanivimab and Etesevimab in Mild to Moderate COVID-19
NCT04427501Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Jun 2020
- Primary completion
- Feb 2023
- Modality
- Antibody Conjugates, Recombinant Proteins and Enzymes, Engineered Antibody Formats
- Countries
- 1
01
Overview
A Phase 3 trial of bamlanivimab, etesevimab, bebtelovimab in coronavirus disease 2019 (COVID-19), sponsored by Eli Lilly and Company. Started Jun 2020; status: completed.
02
Drugs
bamlanivimabetesevimabbebtelovimab
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04427501.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04427501.